Navigation Links
Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
Date:2/11/2008

COPENHAGEN, Denmark, Feb. 11 /PRNewswire/ -- Santaris Pharma, the Danish biopharmaceutical company developing LNA based RNA medicines, announced today that Keith McCullagh, President and Chief Executive Officer, will be presenting an overview of the company and its goals for 2008 at the Biotechnology Industry Organisation's 10th Annual CEO & Investor Conference in New York, today, Monday February 11th at 12:30 pm, US Eastern Standard Time (18:30 Central European Time). The conference is being held at the Waldorf Astoria Hotel, New York City from February 11th-13th, 2008.

A live webcast of the Santaris Pharma presentation may be accessed from the news section of the company's website, http://www.santaris.com, where it will also be archived and available after the presentation.

About Santaris Pharma

Santaris Pharma is a Danish based clinical-stage biopharmaceutical company. The company was formed in 2003 and currently employs around 100 people. Santaris Pharma has the exclusive rights to LNA technology, a 3rd generation antisense chemistry used to develop new classes of RNA medicines, called RNA Antagonists and microRNA antagonists. Santaris Pharma's RNA Antagonists are targeted against tissue specific mRNAs associated with cancer, metabolic disorders and viral disease. In May 2006 Santaris Pharma completed a Euro 40m second round of equity financing and in December 2007 the Company completed a Euro 20m third round of equity financing. Santaris Pharma has a global partnership with Enzon Pharmaceuticals of New Jersey to co-develop and commercialise a series of Santaris Pharma RNA Antagonists for improving the treatment of cancer. GlaxoSmithKline has options to up to four Santaris Pharma drug candidates targeted against viral disease.

For further information please contact

Randi Krogsgaard, Director Corporate Communications

Direct phone: +45 45179879

Cell: +45 20488384

E-mail: rmk@Santaris.com


'/>"/>
SOURCE Santaris Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... -- According to a new market research report "Oligonucleotide ... Equipment), Application (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user ... global market is expected to reach USD 2.20 Billion by 2021 ... during the forecast period. Continue Reading ... ...
(Date:12/8/2016)... 2016  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... cancer immunotherapies, today announced financial results for the ... are delivering on our commitment to address an ... We are pleased with the early clinical response ... we are focused on advancing our lead program ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
Breaking Biology News(10 mins):